Cambridge, MA, May 11, 2005 � Therion Biologics Corporation announces multiple presentations of data on its lead targeted cancer therapy programs at the 2005 American Society of Clinical Oncology (ASCO) meeting, May 14-18, 2005. The two oral presentations and two posters highlight clinical data on Therion�s PANVAC-VF and PROSTVAC-VF programs for pancreatic and prostate cancer. Therion will also have a booth (# 1413) at ASCO to provide scientific information regarding its targeted cancer therapies and highlight the Company�s ongoing clinical trial programs.
�The oral and poster sessions at ASCO both reinforce our clinical development strategy and further demonstrate the potential of our product candidates for commercialization,� commented Thomas J. Schuetz, M.D., Ph.D., Chief Medical Officer at Therion. �These data also continue to support both the safety profile of our core targeted cancer therapy platform and the potential of our drug candidates to selectively target a broad range of solid tumors.�
Data from studies using the Company�s drug candidates will be presented in two oral and two poster sessions. The oral sessions will present (i) safety and preliminary efficacy data from the National Cancer Institute�s (NCI) Phase I/II prostate cancer study and (ii) four year follow-up safety and preliminary efficacy data from the Eastern Cooperative Oncology Group (ECOG) prostate cancer study. The poster sessions will present (i) safety and updated survival data from Therion�s two Phase I pancreatic cancer trials and (ii) safety and preliminary efficacy data from the NCI�s Phase I/II trial in patients with prostate cancer receiving concomitant hormone therapy.
Oral Presentations:
Abstract 2405
J. Gulley (NCI) Monday
May 16 (7:45 am � 10:45 am)
Developmental Therapeutics: Immunotherapy
Abstract 4501
H. Kaufman (ECOG)
Saturday, May 14 (11:15am � 12:30 pm)
Targeted Therapies for Genitourinary Malignancies
Poster Sessions:
Abstract 2576
T. Schuetz (Therion)
Sunday, May 15 (8:00 am � 12:00 pm)
Developmental Therapeutics: Immunotherapy
Abstract 2518
P. Arlen (NCI)
Tuesday, May 17 (8:00am � 12:00 pm)
Developmental Therapeutics: Immunotherapy
About Therion Biologics Corporation
Therion Biologics Corporation is a leader in the development of novel targeted cancer therapeutics designed to selectively seek out and destroy malignant cells without the serious side effects associated with cytotoxic chemotherapy. The company has two lead product candidates:
� PANVAC-VF is in a Phase III registration trial for the treatment of pancreatic cancer;
� PROSTVAC�-VF is in Phase II trials for the treatment of prostate cancer.
In addition to these lead product candidates, clinical trials evaluating Therion�s innovative targeted therapeutics in colorectal, ovarian, breast and lung cancers are also ongoing or planned. Therion�s strategic partners are the National Cancer Institute (NCI) and a network of renowned clinical institutions.
Therion�s technology platform has been validated over a 13-year period in more than 30 clinical trials comprising close to 1000 patients, chiefly through the company�s longstanding partnership with the NCI. This extensive research has enabled Therion to clinically optimize its technology and maximize the probability for downstream success. Therion�s two lead product candidates, PANVAC-VF and PROSTVAC-VF, are a direct result of these efforts.
For more information, please visit www.therion.com
Contacts:
Titus Plattel
Senior Director, Marketing
Therion Biologics Corporation
617.475.7312
www.therion.com
Kari Lampka
MacDougall Biomedical Communications
508.647.0209
[email protected]
